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OR (95% CI)IL-1 b 1.59 (0.30–8.45) 0.92 (0.32–2.60) 0.58 (0.10–3.32)
IL-6 0.27 (0.09–0.79)* 1.15 (0.52–2.52) 4.26 (1.32–13.82)*
IL-1 RA 0.69 (0.22–2.14) 0.55 (0.29–1.07) 0.81 (0.26–2.48)
sIL-6R 0.50 (0.12–2.13) 1.78 (0.54–5.90) 3.53 (0.83–15.13)
TNF-RII 0.29 (0.04–2.42) 0.28 (0.08–0.99)* 0.95 (0.12–7.59)
MCP-1 8.70 (1.46–51.66)* 0.40 (0.11–1.40) 0.05 (0.01–0.36)**
MIG 1.33 (0.73–2.44) 1.02 (0.63–1.65) 0.77 (0.42–1.39)
sBAFF 0.40 (0.13–1.30) 1.86 (0.88–3.93) 4.61 (1.39–15.31)**† values were log normal transformed prior to analysis
**or *p\ .01 or p\ .05, respectively, multinomial logistic regression.
Higher IL-6 levels significantly differentiated participants in
Group 2 from those in Groups 1 and 3. Group 3 had higher TNF-
RII compared to Group 1. Those with higher sBAFF levels were sig-
nificantly more likely to be in Group 2, while those with higher
MCP-1 levels were significantly more likely to be in Group 3.
Conclusion: Allogeneic HSCT survivors with differing cGVHD
symptom profiles were distinguished by significantly different levels
of IL-6, TNF-RII, MCP-1 and sBAFF. These data validate this new
symptom grouping system based on the Lee Chronic GVHD Symp-
tom Scale as a measure of cGVHD disease burden. IL-6, TNF-RII,
MCP-1 and sBAFF appear to be important biomarkers that reflect
specific cGVHD manifestations and merit further study.331
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Based on a clinical association of donor plasmacytoid dendritic cell
(DC) content with leukemia relapses after allo BMT (Waller, Blood
2001), we previously reported that donor CD11b- DC enhanced
IFN-g synthesis and GvL activity of donor T-cells, while CD11b1
DC resulted in increased IL-10 production and decreasedGvL func-
tion by donor T-cells in allo BMT mouse models (Li, Blood 2007).
In this study, we tested mechanisms whereby donor DC in the graft
modulate donor T-cell activation in a MHC-mismatched (C57BL/
6/B10.BR) allo BMT. Recipients received 11 Gy irradiation fol-
lowed by tail vein injection of purified donor HSC, DC subsets
and T-cells two days later. Allografts consisted of 5 104 FACS-pu-
rified donor BM CD11b- DC or CD11b1 DC plus 3  103
c-kit1sca-11lineage- HSC in combination with either 3  105
T-cells or no additional T-cells. In vivo donor-derived T-cell prolif-
eration was assessed by CFSE staining. Serum and intracellular cyto-
kines (Th1: IL-12, IFN-g, IL-2, and TNF-a and Th2: IL-4, IL-5,
and IL-10) were tested by ELISA and flow cytometry. Costimulatory
molecule expression(CD40, CD80, ICOSL, PD-L1 and PD-L2)
was measured by flow cytometry following recovery of GFP1 donor
DC on day110 post-transplant. We found that donor CD8 T-cells
had higher levels of Ki-67 expression and proliferation than donor
CD4 T-cells 3 days post-transplant following transplantation with
CD11b- DC compared with CD11b1 DC, and without donor DC
(p\ 0.001). Both CD11b- DC and CD11b1 DC had similar level
of expression of CD40, CD80, and ICOSL in BM, in lymph nodes
and in spleen at 10 days post-transplant, but CD11b1 donor DC re-covered from BM had much higher levels of PD-L1 than CD11b-
DC,while CD11b-DC in all tissues had higher levels of PD-L2.Do-
nor CD11b- DC enhanced Th1 cytokine production of donor
T-cells, while donorCD11b1DCelevatedTh2 cytokine production
compared with T-cell alone. In conclusion: Donor CD11b- DC en-
hanced donor T-cell proliferation, especially CD8T-cells compared
with donor CD11b1 DC or recipients of T-cells alone. Homing of
donor DC to lymphoid organs and expression of costimulatory mol-
ecules on donor CD11b- and CD11b1DC subsets in vivo were sim-
ilar, suggesting that the differences observed in donor T-cell
activation and proliferation in distinct donor DC subset is likely
due to local production of cytokines by donor DC. The limited
GvHD seen with T-cells injected with CD11b- DC may be due to
differential expression of PD-L2 compared with CD11b1 DC.332
C-FLIP EXPRESSION DETERMINES LOW SENSITIVITY OF TYPE 17 T
HELPER CELLS TO ACTIVATION-INDUCED CELL DEATH
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T cell apoptosis induced by repeated TCR stimulation, known as
activation-induced cell death (AICD), plays an important role in T
cell tolerance. Pro-inflammatory, IL-17-producing CD41 T cells
(Th17 cells) have been recently identified as a unique T helper sub-
set. Preliminary work from our lab indicated that Th17 cells partic-
ipate in the pathogenesis of acute graft-versus-host disease (GVHD).
In this study, we compared the susceptibility of polarized Th1 and
Th17 effectors to AICD in vitro and in vivo. We found that Th17 ef-
fectors were significantly less susceptible to AICD upon TCR re-
stimulation compared to Th1 effectors. It was further confirmed
by Th17 effectors generated from il17f/rfp knock-in mice, RFP1
(Th17) cells were indeed more resistant to AICD than RFP- (non-
Th17) cells. Resistance of Th17 cells to AICD was also observed
when Th17 cells were co-cultured with Th1 cells in vitro or co-in-
jected with Th1 cells in vivo in allogeneic recipients. To explore
the molecular mechanism of AICD resistance in Th17 cells, we
found that Th17 cells were defective in expression of FasL and in ac-
tivation of caspases, but highly expressed anti-apoptotic protein c-
FLIP as compared to Th1 cells. Given that Th17 cells were resistant
to AICD when co-cultured with Th1 cells that express high levels of
FasL, we hypothesized that Fas-signaling was impaired on Th17 ef-
fectors. After knocking down c-FLIP with its specific siRNA, Th17
cells upregulated FasL and underwent rapid apoptosis uponTCR re-
stimulation, indicating that Th17 cells are resistant to AICD likely
because the high level of c-FLIP prevents Fas-mediated apoptosis.
These results suggest the resistance of Th17 cells to AICD as addi-
tional mechanism that contributes to the high pathogenicity of Th17
cells in autoimmune diseases and GVHD. Our finding also
strengthens the rationale to use tumor-specific Th17 cells for adop-
tive cell therapy in cancer.333
MESENCHYMAL STEM CELL INFUSION AS PREVENTION FOR GRAFT RE-
JECTION AND GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HEMA-
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CONDITIONING FROM HLA-MISMATCHED DONORS: A PILOT STUDY
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Background: Allogeneic hematopoietic cell transplantation
(HCT) following nonmyeloablative conditioning has been an effec-
tive treatment for many pts with hematological malignancies who
have a HLA-matched related or unrelated donor. However, results
of nonmyeloablative HCT in pts with HLA-mismatched donors
have been disappointing due to high incidence of graft rejection
and severe acuteGVHD.Recent studies have suggested that infusion
of mesynchymal stem cells (MSC) the day of HCT might promote
engraftment and prevent acute GVHD after myeloablative alloge-
neic HCT. This prompted us to investigate whether MSC infusion
a few hours before HCT could allow non-myeloablative HCT
from HLA-mismatched donors to be performed safely (i.e. with
a 100-day incidence of nonrelapse mortality\35%).
